ILiAD Biotechnologies closed an oversubscribed $115 million Series B led by RA Capital to advance BPZE1, a live attenuated intranasal pertussis vaccine, toward Phase III development and a pivotal human challenge study in 2026. The financing included new institutional backers and existing supporters; ILiAD says proceeds will fund global development and expanded indication planning. BPZE1 is designed to induce both mucosal and systemic immunity and has already shown promise in six clinical studies, including a human challenge trial published in The Lancet Microbe. ILiAD plans neonatal and adolescent development paths and expects initial pivotal data in 2027.